Market Challenges And Opportunities

Global Plasma Therapy Market– Driver

Increasing collaborations among pharmaceutical and biopharmaceutical companies

Collaborations and partnerships between pharmaceutical companies are a major factor leading to the high demand for plasma therapy. For instance, in Novemebr 2022, CSL, an Australia-based multinational specialty biotechnology company, announced a license agreement with Translational Sciences, Inc., a targeted drug therapy provider, to license TS23, an anti-α2-antiplasmin monoclonal antibody. TS23 is being developed to dissolve thrombi that cause serious conditions such as pulmonary embolism (PE) and acute ischemic stroke (AIS). The treatment candidate is soon to be evaluated in the U.S. in the NAIL-IT Phase II study, which has been designed to evaluate the safety and thrombolytic effect of ascending doses of TS23 in patients with sub-massive (intermediate risk) PE.

Establishment of newer technologies regarding plasma therapy

The development of new technologies regarding plasma therapy can drive the growth of the global plasma therapy market. For instance, in March 2021, Grifols, S.A, a developer of plasma-derived therapies and diagnostic solutions, announced its first-ever installation in North America of the DG Reader Net semi-automated analyzer, used to facilitate pre-transfusion blood type compatibility testing.

Global Plasma Therapy Market: Restraint

Potential side-effects of Platelet-Rich Plasma Therapy

The side-effects of Platelet-Rich Plasma Therapy can restrain the growth of the global plasma therapy market. Some people who have undergone PRP therapy complain about an acute ache or soreness in the spot of the injection. Sometimes this pain is even felt deep inside the area, whether in the muscle or bone.